Figure 2. mtDNA somatic substitutions of human cancer.
(A) Number of somatic substitutions in a tumor sample. (B) Average number of somatic substitutions per sample across 31 tumor types. (C) Age of diagnosis and number of mtDNA somatic substitutions in breast cancers.
Figure 2—figure supplement 1. VAFs of phased somatic mtDNA substitutions.
This figure presents VAF pairs between co-clonal, sub-clonal, and
different strand mtDNA substitutions. We expect similar VAFs for
co-clonal pairs; lower VAF in sub-clonal mutations compared to clonal
ones; and sum of a VAF pair is equal or less than 1.0.